MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway

Table 1. Correlation between the clinicopathologic characteristics and miR-1296 and SRPK1 expression in HCC (n = 126)

Clinical parameters	Cases	Expression level		P value	Expression level		P value
Clinical parameters	Cases	MiR-1296^high (n=60)	MiR-1296^low (n=66)	P value	SRPK1^high (n=68)	SRPK1^low (n=58)	P value
Age(years)
<65	67	31	36	0.746	37	30	0.763
≥65	59	29	30		31	28
Gender
Male	100	49	51	0.543	55	45	0.649
Female	26	11	15		13	13
Tumor size (cm)
<5	95	46	49	0.752	50	45	0.598
≥5	31	14	17		18	13
Tumor number
Solitary	107	56	51	0.012*	56	51	0.383
Multiple	19	4	15		12	7
Edmondson
I+II	89	43	46	0.808	47	42	0.686
III+IV	37	17	20		21	16
TNM stage
I+II	99	53	46	0.011*	46	53	0.001*
III+IV	27	7	20		22	5
Capsular
Present	85	41	44	0.842	43	42	0.273
Absent	41	19	22		25	16
Venous invasion
Present	12	2	10	0.024*	11	1	0.006*
Absent	114	58	56		57	57
AFP (ng/mL)
<400	39	17	22	0.544	23	16	0.450
≥400	87	43	44		45	42
HBsAg
Positive	116	56	60	0.615	61	55	0.466
Negative	10	4	6		7	3

HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis. *Statistically significant

ISSN: 1476-4598